Abstracts tagged "Antiphospholipid antibodies"

Abstract Number: 15 • 2014 ACR/ARHP Annual Meeting
Performance of an Automated Chemiluminescence Assay for Anti-Cardiolipin and Anti-Beta2glycoprotein I Antibodies Detection in a Cohort of 400 Clinically Characterized Consecutive Routine Samples
Alessandra Zanola¹, Laura Andreoli¹, Cecilia Nalli¹, Flavio Allegri¹, Michael Mahler², Gary Norman³ and Angela Tincani¹, ¹Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ²Research, INOVA Diagnostics, San Diego, CA, ³INOVA Diagnostics, San Diego, CA
Background/Purpose: Several immunoassays are available for the detection of anti-cardiolipin (aCL) and anti-beta2glycoprotein I antibodies (anti-B2GPI), but standardization and harmonization of these tests is an…
Abstract Number: 10 • 2014 ACR/ARHP Annual Meeting
Antiphospholipid Antibodies and Neuropsychiatric Events in Pediatric Patients
Mileka Gilbert¹ and Lenore M. Buckley², ¹Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX, ²Section of Rheumatology, Yale School of Medicine, New Haven, CT
Background/Purpose: An association between anti-phospholipid antibodies (aPL abs) and non-thrombotic neuropsychiatric events has been reported in pediatric and adult patients, including patients who do not…
Abstract Number: 5 • 2014 ACR/ARHP Annual Meeting
Antiphospholipid-Associated Nephropathy Is a Risk for Developing Arterial Thromboses in Patients with Systemic Lupus Erythematosus
Tomoko Fukui, Shinsuke Yasuda, Toshiyuki Watanabe, Kazumasa Ohmura, Sanae Shimamura, Ikuma Nakagawa, Atsushi Noguchi, Haruki Shida, Yuka Shimizu, Michihito Kono, Takashi Kurita, Kenji Oku, Toshiyuki Bohgaki, Olga Amengual, Tetsuya Horita and Tatsuya Atsumi, Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
Background/Purpose: Antiphospholipid-associated nephropathy (APLN) is characterized by coexistence of antiphospholipid antibodies (aPLs) and renal small-vessel vasculopathy/chronic renal ischemia. Consequences of APLN to thrombosis have yet…
Abstract Number: 4 • 2014 ACR/ARHP Annual Meeting
Detection of Anti-Beta2glycoprotein I Domain 1 Antibodies By an Automated Chemiluminescence Assay in a Cohort of 400 Clinically Characterized Consecutive Routine Samples
Laura Andreoli¹, Alessandra Zanola¹, Cecilia Nalli¹, Flavio Allegri¹, Michael Mahler², Gary Norman³ and Angela Tincani¹, ¹Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ²9900 Old Grove road, INOVA Diagnostics, San Diego, CA, ³INOVA Diagnostics, San Diego, CA
Background/Purpose: Several studies suggested that antibodies to Domain 1 of beta2glycoprotein I (a-B2GPI-D1) represent a promising biomarker for the diagnosis and risk assessment of Antiphospholipid…
Abstract Number: 2 • 2014 ACR/ARHP Annual Meeting
Thrombocytopenia in Primary Antiphospholipid Syndrome Is Related to Arterial Thrombosis
Ikuma Nakagawa¹, Kenji Oku², Olga Amengual¹, Ryo Hisada¹, Eri Sugawara¹, Kazumasa Ohmura¹, Tomoko Fukui¹, Sanae Shimamura¹, Haruki Shida¹, Toshiyuki Watanabe¹, Yuka Shimizu¹, Michihito Kono¹, Takashi Kurita¹, Toshiyuki Bohgaki¹, Tetsuya Horita¹, Shinsuke Yasuda¹ and Tatsuya Atsumi¹, ¹Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ²Medicine II, Hokkaido University Graduate School of Medicine, Sapporo, Japan
Background/Purpose: Antiphospholipid-associated syndrome refers to organ dysfunctions developed in the existence of antiphospholipid antibodies (aPL), apart from the typical manifestations of antiphospholipid syndrome (APS) such…
Abstract Number: 2864 • 2014 ACR/ARHP Annual Meeting
Markers of Thrombotic Events in Autoimmune Diseases:Comparison of Antiphospholipid Score (aPL-S) and Global Anti-Phospholipid Syndrome Score (GAPSS)
Kenji Oku, Olga Amengual, Ryo Hisada, Kazumasa Oomura, Ikuma Nakagawa, Toshiyuki Watanabe, Toshiyuki Bohgaki, Tetsuya Horita, Shinsuke Yasuda and Tatsuya Atsumi, Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
Background/Purpose Recently, new scoring systems to quantify the probability for the diagnosis of antiphospholipid syndrome (APS) have been proposed in sequence: the Antiphospholipid Score(aPL-S) and…
Abstract Number: 2651 • 2013 ACR/ARHP Annual Meeting
The Association Between Antiphospolipid Antibodies and Related Clinical Outcomes: A Critical Review Of The Literature
Cecilia B. Chighizola¹, Laura Andreoli², Alessandra Banzato³, Guilherme Ramires de Jesus⁴, Guillermo J. Pons-Estel⁵, Doruk Erkan⁶ and On Behalf of APS Action⁷, ¹Rheumatology, Istituto Auxologico Italiano, University of Milan, Cusano Milanino, Italy, ²Rheumatology Unit, University of Brescia, Brescia, Italy, ³Department of Cardiac Thoracic and Vascular Sciences, Department of Cardiac Thoracic and Vascular Sciences, University of Padua, Padua, Italy, ⁴Department of Obstetrics, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ⁵Servicio de Enfermedades Autoinmunes, Department of Autoimmune Diseases, Institut Clìnic de Medicina i Dermatologia, Hospital Clìnic, Barcelona, Spain, ⁶Rheumatology, Hospital for Special Surgery, New York, NY, ⁷APS ACTION, New York, NY
Background/Purpose: AntiPhospholipid Syndrome Alliance For Clinical Trials and InternatiOnal Networking (APS ACTION) is an international network that has been created to design and conduct APS…
Abstract Number: 2654 • 2013 ACR/ARHP Annual Meeting
IgG Antibodies Directed Against Domain I Of ß₂-Glycoprotein I Are Significant Predictors Of Thromboembolic Events In Patients With Antiphospholipid Antibodies. A Prospective Cohort Study
Stephane Zuily¹, Bas de Laat², Francis Guillemin³, Pierre Kaminsky⁴, Hilde Kelchtermans⁵, Roger Albesa⁶, Gary L. Norman⁶, Anne-Christine Rat⁷, Philip de Groot⁸, Thomas Lecompte⁹, Veronique Regnault¹⁰ and Denis Wahl¹, ¹CHU de Nancy, Vascular Medicine Division and Regional Competence Center For Rare Vascular And Systemic Autoimmune Diseases, Nancy, F-54000, France; Inserm, UMR_S 1116, Nancy, F-54000, France; Université de Lorraine, Nancy, F-54000, France, Nancy, France, ²Biochemistry, CARIM, Maastricht University, The Netherlands; Clinical Chemistry and Hematology, UMC Utrecht, The Netherlands; Synapse BV, Maastricht, The Netherlands; Sanquin Research, Amsterdam, The Netherlands, Maastricht, Netherlands, ³CHU Nancy, Clinical Epidemiology and Evaluation, Université de Lorraine, Paris Descartes University, APEMAC, EA 4360, Nancy, France, ⁴Université de Lorraine, Nancy, F-54000, France; CHU de Nancy, Orphan disease unit, Nancy, F-54000, France;, Nancy, France, ⁵Biochemistry, CARIM, Maastricht University, The Netherlands; Synapse BV, Maastricht, The Netherlands, Maastricht, Netherlands, ⁶Research, INOVA Diagnostics, San Diego, CA, ⁷Université de Lorraine, Nancy, F-54000, France; Inserm, CIC-EC CIE6, Nancy, F-54000, France; CHU de Nancy, Clinical Epidemiology and Evaluation Department, Nancy, F-54000, France; CHU de Nancy, Rheumatology department, Nancy, France, ⁸Clinical Chemistry and Hematology, UMC Utrecht, The Netherlands, Utrecht, Netherlands, ⁹Inserm, UMR_S 1116, Nancy, F-54000, France; Université de Lorraine, Nancy, F-54000, France; CHU de Nancy, Haematology Laboratory, Nancy, F-54000, France; Division of Haematology, HUG, Geneva, Switzerland (current address), Geneva, Switzerland, ¹⁰Inserm, UMR_S 1116, Nancy, F-54000, France; Université de Lorraine, Nancy, F-54000, France; CHU de Nancy, Contrat d’interface, Nancy, F-54000, France, Nancy, France
AbstractBackground/Purpose : Our objective was to prospectively determine the prognostic significance of laboratory variables regarding thrombotic events during follow-up, including novel assays IgG antibodies directed…
Abstract Number: 556 • 2013 ACR/ARHP Annual Meeting
Depletion Of The Gut Microbiota Prevents β₂-Glycoprotein I Antibody Production and Mortality In a Model Of Antiphospholipid Syndrome
Silvio M. Vieira¹, Andrew Yu¹, Odelya E. Pagovich¹, Eleni Tiniakou², John Sterpka¹ and Martin A. Kriegel^3,4, ¹Yale School of Medicine, New Haven, CT, ²Yale University School of Medicine, New Haven, CT, ³Immunobiology, Yale School of Medicine, New Haven, CT, ⁴Medicine/Division of Rheumatology, Yale School of Medicine, New Haven, CT
Background/Purpose: Infectious triggers have been implicated in transient antiphospholipid antibody production in both mice and humans. The cause of persistent anti-β2-glycoprotein I (β2GPI) antibody production…
Abstract Number: 19 • 2013 ACR/ARHP Annual Meeting
Association Of Antiphospholipid Antibodied Detected In The Aphl ELISA With Clinical Manifestations Of The Antiphospholipid Syndrome In Two Lupus Cohorts
Silvia S. Pierangeli¹, Rohan Willis², Michelle Petri³, Hong Fang⁴, Monica Smikle⁵, Karel de Ceulaer⁶ and E. Nigel Harris⁷, ¹Rheumatology/Dept Int Med, University of Texas Medical Branch, Galveston, TX, ²Int Medicine/Rheumatology, University of Texas Medical Branch, Galveston, TX, ³Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Div of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Microbiology, University of the West Indies, Kgn 7, Jamaica, ⁶Microbiology, University of the West Indies, KIngston, Jamaica, ⁷Office of the Vice Chancellor, The University of the West Ind, Kingston, Jamaica
Background/Purpose: Antiphospholipid Syndrome (APS) is characterized by the presence of antibodies to phospholipid (aPL) and to β2glycoprotein I (β2GPI) in patients with thrombosis or pregnancy…
Abstract Number: 3 • 2013 ACR/ARHP Annual Meeting
The Global Antiphospholipid Syndrome Score (GAPSS) In Primary APS
Savino Sciascia¹, Giovanni Sanna², Veronica Murru³, Dario Roccatello¹, Munther A. Khamashta⁴ and Maria Laura Bertolaccini³, ¹Department of Rare, Immunologic, Hematologic and Immunohematologic Diseases, Centro di Immunopatologia e Documentazione su Malattie rare, Torino, Italy, ²Louise Coote Lupus Unit, St. Thomas' Hospital, London, United Kingdom, ³Lupus Research Unit, The Rayne Institute, Kings College London School of Medicine, London, United Kingdom, ⁴Lupus Research Unit, The Rayne Institute, St Thomas Hospital, Kings College London School of Medicine, London, United Kingdom
Background/Purpose: Antiphospholipid Syndrome (APS) is a heterogeneous entity with a wide variation in clinical course and laboratory profile. We aimed to evaluate the clinical utility…
Abstract Number: 4 • 2013 ACR/ARHP Annual Meeting
Proteomic Analyses Of Monocyte Responses To IgG From Patients With Antiphospholipid Syndrome
Vera M. Ripoll¹, Anastasia Lambrianides², Wendy Heywood³, Anisur Rahman⁴, Yiannis Ioannou⁵ and Ian Giles⁶, ¹Centre for Rheumatology, Rayne Institute, 4th floor, Centre for Rheumatology, University College London, London, United Kingdom, ²Centre for Rheumatology Research, University College London, London, United Kingdom, ³Institute of Child Health, University College London, London, United Kingdom, ⁴Centre for Rheumatology Research,Rayne Institute, 4th Floor, University College London, London, United Kingdom, ⁵Arthritis Research UK Centre for Adolescent Rheumatology, University College London, London, United Kingdom, ⁶Centre for Rheumatology, Division of Medicine, Centre for Rheumatology, University College London, London, United Kingdom
Background/Purpose: Antiphospholipid syndrome (APS) is an autoimmune disorder characterised by recurrent vascular thrombosis (VT) and/or pregnancy morbidity (PM) caused by antiphospholipid antibodies (aPL). Whilst aPL are known…
Abstract Number: 8 • 2013 ACR/ARHP Annual Meeting
Clinical Evaluation Of Two Anti-Beta₂glycoprotein I Domain 1 Autoantibody Assays To Aid In The Diagnosis and Risk Assessment Of The Antiphospholipid Syndrome
Rohan Willis¹, Michael Mahler², Francesca Pregnolato³, Charis Pericleous⁴, Anisur Rahman⁵, John Ioannou⁶, Ian Giles⁵, Gabriella Lakos², Roger Albesa², Navid Zohoury², Pier-Luigi Meroni⁷ and Silvia S. Pierangeli⁸, ¹Int Medicine/Rheumatology, University of Texas Medical Branch, Galveston, TX, ²Research, INOVA Diagnostics, San Diego, CA, ³Lab of Immunology, IRCCS Istituto Auxologico Italiano, Milan, Italy, ⁴Centre for Rheumatology, Division of Medicine, Centre for Rheumatology, University College London, London, United Kingdom, ⁵Centre for Rheumatology Research,Rayne Institute, 4th Floor, University College London, London, United Kingdom, ⁶Rayne Institute, University College London, London, UK, London, United Kingdom, ⁷Int Medicine, University of Milan, Milano, Italy, ⁸Rheumatology/Dept Int Med, University of Texas Medical Branch, Galveston, TX
Background/Purpose: Antiphospholipid Syndrome (APS) is characterized by the presence of antibodies to phospholipids (aPL) and to β2glycoprotein I (β2GPI) in patients with thrombosis or pregnancy…
Abstract Number: 9 • 2013 ACR/ARHP Annual Meeting
Domain 1 Is The Main Specificity Of Anti-β₂glycoprotein I Antibodies In Systemic Autoimmune Diseases
Laura Andreoli¹, Cecilia Nalli¹, Maria-Orietta Borghi², Francesca Pregnolato³, Alessandra Zanola⁴, Claudia Grossi⁵, Maria Gerosa⁶, Flavio Allegri⁴, Michael Mahler⁷, Gary L. Norman⁷, Pier Luigi Meroni⁸ and Angela Tincani¹, ¹Rheumatology Unit, University of Brescia, Brescia, Italy, ²Lab of immunology, IRCCS Istituto Auxologico Italiano, Department of Clinical Sciences and Community Health, University of Milan, Milano, Italy, ³Lab of Immunology, IRCCS Istituto Auxologico Italiano, Milan, Italy, ⁴Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ⁵Laboratory of Immuno-rheumatology, IRCCS Istituto Auxologico Italiano, Milan, Italy, ⁶Division of Rheumatology, Gaetano Pini Institute, Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy, ⁷Research, INOVA Diagnostics, San Diego, CA, ⁸Division of Rheumatology, Gaetano Pini Institute, Milano, Italy
Background/Purpose: Anti-β2glycoprotein I antibodies (a-β2GPI) are involved in the pathogenesis of the Antiphospholipid Syndrome (APS). Antibodies to the domain 1 of β2GP1 (a-β2GPI-D1) have been…
Abstract Number: 10 • 2013 ACR/ARHP Annual Meeting
Autoantibodies Targeting Domain 1 Of Beta 2 Glycoprotein I As Promising Marker In The Diagnosis and Risk Stratification Of The Antiphospholipid Syndrome
Navid Zohoury¹, Munther A. Khamashta², Tatsuya Atsumi³, Jacek Musial⁴, Toshiyuki Watanabe⁵, Maria Papp⁶, Concepción González-Rodríguez⁷, Roger Albesa¹, Gary L. Norman¹, Pier-Luigi Meroni⁸ and Michael Mahler¹, ¹Research, INOVA Diagnostics, San Diego, CA, ²Lupus Research Unit, The Rayne Institute, St Thomas Hospital, Kings College London School of Medicine, London, United Kingdom, ³Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ⁴Depment of Medicine, Jagiellonian University Medical College, Krakow, Poland, ⁵Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Hokkaido, Japan, ⁶MHSCInstitute of Medicine, Department of Gastroenterology, University of Debrecen, Debrecen, Hungary, ⁷University Hospital Virgen Macarena, Sevilla, Spain, ⁸Int Medicine, University of Milan, Milano, Italy
Background/Purpose: Antiphospholipid Syndrome (APS) is characterized by the presence of antibodies to phospholipids (aPL) and to β2glycoprotein I (β2GPI) in patients with thrombosis or pregnancy…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].